Anteris Technologies Global Corp.
AVRHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Anteris Technologies Global Corp. focuses on Medical Devices services and products. Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. Valued at $840.1M, AVR is a small-cap name in its sector. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve.
Market Cap
$840.1M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-8.93
EPS (TTM)
$-1.95
EPS (Fwd)
$-0.96
ROE
-74.7%
ROA
-42.5%
Cash
$256.9M
Total Debt
$3.3M
Free CF
-$51.1M
52W Change
87.5%
Annual Financials
Cash vs Debt
Where AVR stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, AVR finished 15.26% above its 150-day moving average ($7.47) and 26.80% above its 200-day moving average ($6.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVR overbought or oversold?
At the September 1, 2026 close, AVR's RSI(14) was 40.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $256.9M in cash and $3.3M in debt, AVR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$51.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -74.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $3.1M (2022) to $1.9M (2025), a 39% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Anteris Technologies Global Corp.'s trajectory.